Both initial public offerings (IPOs) on last week's calendar succeeded in entering the public markets and another five are on the calendar for the coming week. Last week's capital raise of about $132 million is dwarfed by the $966 million being sought in the week ahead.
Of last week's IPOs, Akcea Therapeutics Inc. (AKCA) raised $125 million in an upsized offering of 15.6 million shares at a reduced price of $8 a share. The stock got a first-day pop of 18.5% on Friday.
Co-Diagnostics Inc. (CODX) raised $7 million with a downsized offering of 1.2 million shares at $6 a share, below the expected range of $6.35 to $6.75. Shares closed the week essentially flat.
ALSO READ: America's Deadliest Cars
Through the week ending July 14 IPO ETF manager Renaissance Capital reported that 79 IPOs have priced in the U.S. so far this year, up nearly 80% year over year. Total proceeds raised through last week equaled $20.6 billion, up 182% year over year. For 2016, Renaissance Capital reported a total of 105 IPOs, down 38% year over year from 170 in 2015. Total 2016 proceeds amounted to $18.8 billion compared with a 2015 total of $30 billion. Renaissance Capital does not include “best efforts” or blank-check companies in its totals, nor does it include IPOs that raise less than $10 million.
First out of the gate this week is Calyxt Inc., a spin-off of Cellectis (CLLS), that develops gene-edited crop traits. The company plans to offer 6.1 million shares in an expected price range of $15 to $18 to raise $100 million at an implied market cap of $440 million. Underwriters are Citi, Jefferies, Wells Fargo Securities, BMO Capital Markets, and Ladenburg Thalmann & Co. Shares are expected to price Wednesday and begin trading Thursday on the Nasdaq under the ticker symbol CLXT.
ALSO READ: 15 Places Most Vulnerable to Sea Level Rise
Federal Street Acquisition Corp. is a blank-check company that plans to acquire a healthcare business. The firm is offering 40 million units at a price of $10. Each unit consists of one share of Class A common stock and one-half of one warrant to purchase further shares at a price of $11.50 within five years. Underwriters for the offering are Citi and BofA/Merrill Lynch. Units begin trading Thursday on the Nasdaq under the ticker symbol FSACU.
Kala Pharmaceuticals Inc. is a biopharmaceutical company using proprietary technology to focus on treatment of eye diseases. The firm plans to offer 6 million shares in an expected price range of $14 to $16 to raise $90 million at an implied market cap of $349 million. Underwriters include J.P. Morgan, BofA/Merrill Lynch, Wells Fargo Securities, and Wedbush PacGrow. Shares are set to price Wednesday and begin trading Thursday on the Nasdaq under the ticker symbol KALA.